10x Genomics Ret. on equity
What is the Ret. on equity of 10x Genomics?
The Ret. on equity of 10x Genomics, Inc. is -32.74%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to 10x Genomics
What does 10x Genomics do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Companies with ret. on equity similar to 10x Genomics
- Keypath Education Internat Inc has Ret. on equity of -32.81%
- Jabbo Capital has Ret. on equity of -32.81%
- Bicycle Therapeutics plc has Ret. on equity of -32.80%
- Predator Oil & Gas Plc has Ret. on equity of -32.78%
- World Super has Ret. on equity of -32.78%
- Keras Resources Plc has Ret. on equity of -32.76%
- 10x Genomics has Ret. on equity of -32.74%
- comScore has Ret. on equity of -32.72%
- comScore has Ret. on equity of -32.72%
- comScore has Ret. on equity of -32.72%
- comScore has Ret. on equity of -32.72%
- comScore has Ret. on equity of -32.72%
- comScore has Ret. on equity of -32.72%